Drug Development

Articles

GeoVax has received a patent for its malaria vaccine from the US Patent and Trademark Office.

USPTO Issues Malaria Vaccine Patent to GeoVax

Pfizer and BioNTech have submitted an application for Emergency Use Authorization for a COVID-19 vaccine booster dose in young children. 

Pfizer and BioNTech Submit EUA Application for Pediatric COVID-19 Vaccine Booster Dose

EMA has granted Novo Nordisk a positive scientific opinion on human insulin with more flexible storage without refrigeration.

Novo Nordisk Announces Positive Scientific Opinion from EMA on Human Insulin

The European Investment Bank has provided €15 million to fund coronavirus research at IRBM.

EIB Provides €15 million to IRBM

Meg Rivers is the former senior editor for 

Podcasts

In this episode of the Drug Solutions Podcast, Meg Rivers, senior editor, interviews Joy Aho, senior product manager at Be The Match BioTherapies, about sourcing autologous and allogeneic cell therapies.

Drug Solutions Podcast: Sourcing Autologous and Allogeneic Cell Therapies

ReiThera and Exothera are collaborating to develop a large-scale, low-cost-per-dose manufacturing process to deliver novel vaccines to low and middle-income countries.

ReiThera and Exothera Collaborate on Manufacturing Vaccines for Low and Middle-income Countries

Swissmedic grants conditional marketing authorization for Novavax COVID-19 vaccine for individuals aged 18 years or older in Switzerland. 

Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

Dupixent has been approved by the EC for children aged 6 to 11 years with severe asthma with type 2 inflammation.

EC Approves Dupixent for Treatment of Severe Asthma in Young Children

FDA has granted Priority Review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalized adults.

FDA Grants Priority Review to Intravenous Treatment of COVID-19 in Hospitalized Adults

ECDC and EMA have concluded that it is too early to consider using a fourth dose of mRNA COVID-19 vaccines in the general population.

Formulation and Drug Delivery